Endocrine therapy and other targeted therapies for metastatic breast cancer

References

• Guarneri V, Conte PE The curability of breast cancer and the treatment of advanced disease. Eur. J Nucl. Med. Mol. Imaging 30\(Suppl. 1), 149–161 (2004).
   Google Scholar
• Dow KH. Existing and emerging endocrine therapies for breast cancer. Cancer Nurs. 25 (Suppl. 2), 6–11 (2002).
   Google Scholar
• Mouridsen HT, Rose C, Brodie Aft Smith IE. Challenges in the endocrine management of breast cancer. Breast 12 (Suppl. 2), 2–19 (2003).
   Google Scholar
• Piccart M, Parker LM, Pritchard KL Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Ann. Oncol. 14(7), 1017–1025 (2003).
   PubMedGoogle Scholar
• Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer90(Suppl. I), S2—S6 (2004).
   Google Scholar
• Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 90 (Suppl. 1), S15—S18 (2004).
   Google Scholar
• Ring A, Dowsett M. Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clin. Breast Cancer (4 Suppl. 1), 534—S41 (2003).
   Google Scholar
• Simpson ER, Mahendroo MS, Means GD et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev 15, 342–355 (1994).
   Google Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl. J Med. 348(24), 2431–2442 (2003).
   Google Scholar
• Reed MJ, Owen AM, Lai LC et al. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. Int. J Cancer 44, 233–237 (1989). ii Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM, Telford J. Regulation of aromatase activity within the breast. J Steroid Biochem. Mol. Biol. 61, 193–202 (1997).
   Google Scholar
• Gershanovich M, Chaudri HA, Campos D et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann. Oncol. 9, 639–645 (1998).
   Google Scholar
• Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 16, 453–461 (1998).
   PubMed Web of Science ®Google Scholar
• Buzdar A, Douma J, Davidson N et al. Phase III, multicentre, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19, 3357–3366 (2001).
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourda P, Webster A. A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79,730–739 (1997).
   Google Scholar
• Jonat W, Howell A, Blomqvist C et al. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J Cancer 32A, 404–412 (1996).
   PubMed Web of Science ®Google Scholar
• Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin. OncoL 18,1399–1411 (2000).
   PubMed Web of Science ®Google Scholar
• Rose C, Vtoraya O, Pluzanska A et al. An open randomized trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur. Cancer39, 2318–2327 (2003).
   PubMed Web of Science ®Google Scholar
• Bhatnagar AS, Brodie AM, Long BJ, Evans DB, Miller WR. Intracellular aromatase and its relevance to the pharmacologic efficacy of aromatase inhibitors. J Steroid Biochem. MoL BioL 76,199–202 (2001).
   Google Scholar
• Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin. Oncol. 20,751–757 (2002).
   Google Scholar
• Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J Clin. OncoL 11, 2234–2244 (2000).
   Google Scholar
• •Conducted to evaluate the antitumor activity and toxicity of exemestane in postmenopausal women with metastatic breast cancer who had progressive disease after treatment with a nonsteroidal aromatase inhibitor. Concluded that exemestane 25 mg once daily seems to be an attractive alternative to chemotherapy.
   Google Scholar
• Bonneterre J, Thiirlimann B, Robertson JFR et aL for the Arimidex Study Group. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J. Clin. OncoL 18(22), 3748–3757 (2000).
   Google Scholar
• ••Conducted to compare the efficacy andtolerability of anastrozole with that of tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. This randomized, double-blind, multicenter study evaluated the efficacy of anastrozole 1 mg once daily relative to tamoxifen 20 mg once daily in patients with tumors that were hormone receptor-positive or of unknown receptor status who were eligible for endocrine therapy. Anastrozole satisfied the predefined criteria for equivalence to tamoxifen. Findings indicated that anastrozole should be considered as first-line therapy.
   Google Scholar
• Nabholtz JM, Buzdar A, Pollak M et al. for the Arimidex Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin. OncoL 18(22), 3758–3767 (2000).
   Google Scholar
• ••The efficacy and tolerability of anastrozoleand tamoxifen were compared as first-line therapy for advanced breast cancer. Anastrozole satisfied the predefined criteria for equivalence to tamoxifen. Both a significant increase in time to progression and a lower incidence of thromboembolic events and vaginal bleeding with anastrozole were observed. Findings indicate that anastrozole should be considered as first-line therapy.
   Google Scholar
• Mourisden H, Gershonovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21 (11), 2101–2109 (2003).
   Google Scholar
• •• Multicenter Phase III trial randomly assigned 916 patients with hormone receptor-positive or unknown tumors to letrozole 2.5 mg (n = 458) or tamoxifen 20 mg (n = 458) daily until disease progression. Optional cross-over was permitted. The superiority of letrozole to tamoxifen was confirmed for time to progression, time to treatment failure, overall objective response rate and overall clinical benefit. Median overall survival was slightly prolonged for the randomized letrozole arm.
   Google Scholar
• Paridaens R, Dirix L, Lohrisch C et al. on behalf of EORTC. Mature results of a randomized Phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. OncoL 14(9), 1391–1398 (2003). Explored the efficacy and safety of exemestane as first-line hormonal therapy in metastatic breast cancer in postmenopausal women. Exemestane was well tolerated and active in the first-line treatment of hormone-responsive metastatic breast cancer.
   Google Scholar
• Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) — A randomized phase III trial of the EORTC Breast Group. Proc. Am. Soc. Clin. OncoL (2004) (Abstract 515).
   Google Scholar
• Howell A, Robertson JF, Vergote I. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res. Treat. 82(3), 215–222 (2003).
   Google Scholar
• Celio L, Martinetti A, Ferrari L et al. Premenopausal breast cancer patients treated with a gonadotrophin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res. 19(3B), 2261–2268 (1999).
   Google Scholar
• Forward DP, Cheung KL, Jackson L, Robertson JFR. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br. J Cancer 90, 590–594 (2004)
   PubMed Web of Science ®Google Scholar
• Maguire HC, Greene MI. The neu (c-erbB-2) oncogene. Semin. Oncol 16, 148–155 (1989).
   Google Scholar
• Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 51, 944–948 (1991).
   PubMed Web of Science ®Google Scholar
• Lupu R, Lippman ME. The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res. Treat. 27, 83–93 (1993).
   Google Scholar
• Wright C, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 49(8), 2087–2090 (1989).
   Google Scholar
• Lipton A, Ali SM, Leitzel K. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin. Om& 20, 1467–1472 (2002).
   Google Scholar
• Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. j Clin. Oncol. 21,1967-1972 (2003).
   Google Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin. OncoL 19(18), 3808–3816 (2001).
   Google Scholar
• Osborne CK, Jarman M, McCague R et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother. Pharmacol. 34, 89–95 (1994).
   PubMed Web of Science ®Google Scholar
• Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 87, 746–750 (1995).
   PubMed Web of Science ®Google Scholar
• Robertson JF, Nicholson RI, Bundred NJ et al. Comparison of the short-term biologic effects of 7a- [9-(4,4,5,5,5,-pentafluoropentylsulfiny0 -nonyl] estra - 1,3,5, (10)-triene-3,14-diol (Faslodex) versus tamoxifen in postmenopausal women with breast cancer. Cancer Res. 61, 6739–6746 (2001).
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JFR, Quaresma Albano J etal. Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin. OncoL 20, 3396–3403 (2002).
   Google Scholar
• •Compared the efficacy and tolerability of fulvestrant and anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Fulvestrant was found to be as effective as anastrozole and a well-tolerated treatment.
   Google Scholar
• Osborne CK, Pippen J, Jones SE et aL A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Clin. OncoL 20, 3386–3395 (2002).
   Web of Science ®Google Scholar
• •Compared the efficacy and tolerability of fulvestrant with anastrozole in the treatment of advanced breast cancer in patients whose disease progressed on prior endocrine treatment. Fulvestrant was at least as effective as anastrozole, with efficacy end points slightly favouring fulvestrant. Concluded that fulvestrant represents an additional treatment option.
   Google Scholar
• Howell A, Robertson JF, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin. OncoL 22(9), 1605–1613 (2004). In this multicenter, double-blind, randomized trial, patients with metastatic breast cancer previously untreated for advanced disease were randomly assigned to fulvestrant or tamoxifen. In the overall population, between-group differences in efficacy end points favored tamoxifen, and statistical noninferiority of fulvestrant could not be demonstrated. However, in patients with hormone receptor-positive tumors, fulvestrant had similar efficacy to tamoxifen and was well tolerated.
   Google Scholar
• Osborne CK. Tamoxifen in the treatment of breast cancer. N EngL I Med. 339(22), 1609–1618 (1998).
   Google Scholar
• Howell A, DeFriend D, Robertson J, Blamey R, Walton P Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 345(8941), 29–30 (1995).
   Google Scholar
• Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9(1 Pt 2), 447S-454S (2003).
   Google Scholar
• Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. MoL Endocrinol. 11(6), 657–666 (1997).
   Google Scholar
• Lavinsky RM, Jepsen K, Heinzel T et aL Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Nat/Acad. Sci. USA 95(6), 2920–2925 (1998).
   Google Scholar
• Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin. Cancer Res. 7\(Suppl. 12), 4429S-4435S (2001).
   Google Scholar
• Nicholson RI, Gee JMW, Barrow D, McClelland RA. Endocrine resistance in breast cancer can involve a switch towards EGFR signaling pathway and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839. Clin. Cancer Res. 5 (1999) (Abstract 740).
   Google Scholar
• Lupu R, Cardillo M, Cho C et al. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res. Treat. 38 (1), 57–66 (1996).
   Google Scholar
• Osborne CK, Bardou V, Hlsenbeck SG et al. The estrogen receptor coactivator AIB1 (SRC3) in combination with HER-2 is a prognostic and predictive marker in patients with breast cancer. Proc. Am. Soc. Cli. OncoL (2002) (Abstract 129).
   Google Scholar
• Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br. J. Cancer. 82(3), 501–513 (2000).
   Google Scholar
• Druker BJ, Talpaz M, Resta DJ et aL Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N EngL J. Med. 344(14), 1031–1037 (2001).
   Web of Science ®Google Scholar
• Ranson M, Hammond LA, Ferry D et aL ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. OncoL 20(9), 2240–2250 (2002).
   Google Scholar
• Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6(5), 2053–2063 (2000).
   Google Scholar
• Fukuoka M, Yano S, Giaccone G. Final results from a Phase II trial of ZD1839 (Iressa) in patients with advanced nonsmall cell lung cancer (IDEAL-1) Proc. Am. Soc. Clin. OncoL 21, 298a (2002) (Abstract 1188).
   Google Scholar
• Albain K, Elledge R, Gradishar WJ et al. Open-label Phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res. Treat. 76 (2002) (Abstract 20).
   Google Scholar
• Robertson JFR, Gutteridge E, Cheung KL et al. Gefitinib (ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor positive and ER-negative breast cancer: results from a phase II study. Proc. Am. Soc. Clin. OncoL 22 (2003) (Abstract 23).
   Google Scholar
• Winer E, Cobleigh M, Dickler M et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. 76 (2002) (Abstract 445).
   Google Scholar
• Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin. OncoL 29(3 Suppl. 11), 4–10 (2002).
   Google Scholar
• Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin. OncoL 29(3 Suppl. 11), 11–21 (2002).
   Google Scholar
• Clark GJ, Der CJ. Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res. Treat. 35(1), 133–144 (1995).
   Google Scholar
• Kelland LR, Smith V, Valenti M et al. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin. Cancer Res. 7(11), 3544–3550 (2001).
   Google Scholar
• Johnston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin. OncoL 21(13), 2492–2499 (2003).
   Google Scholar
• •• Phase II study in 76 patients with advanced breast cancer recruited two cohorts of patients sequentially. The first (n = 41) received a continuous dosing regimen of R115777 400 or 300 mg. The second (n = 35) received 300 mg in a cyclical regimen of 21 days of treatment followed by 7 days of rest. R115777 demonstrated clinical activity in patients with metastatic breast cancer, and the second regimen had a significantly improved therapeutic index.
   Google Scholar
• Johnston SRD, Hickish T, Ellis PA et al. Clinical activity with the farnesyl transferase inhibitor RU 5777 in patients with advanced breast cancer — relationship with tumour phenotype. Breast Cancer Res. Treat. 64,32 (2000) (Abstract 28).
   Google Scholar
• Johnston SRD, Head J, Valenti M et al. Endocrine therapy combined with the farnesyltransferase inhibitor R115777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in vivo. Breast Cancer Res. Treat. 76 (2002) (Abstract 245).
   Google Scholar
• Shi B, Yaremko B, Hajian G et al. The farnesyl protein transferase inhibitor 5CH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother. PharmacoL 46(5), 387–393 (2000).
   Google Scholar
• Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9 (Suppl. 1), 43–49 (2004).
   Google Scholar
• Yu K, Toral-Barza L, Discafani C et aL mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8 (3), 249–258 (2001).
   Google Scholar
• O'Byrne KJ, Dobbs N, Propper DJ et aL Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br. J. Cancer79(9–10), 1413–1418 (1999).
   Google Scholar
• Ingle JN, Suman VJ, Kardinal CG et aL A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer85(6), 1284–1292 (1999).
   PubMedGoogle Scholar
• Chernicky CL, Tan H, Yi L, Loret de Mola JR, Ilan J. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo. MoL Path& 55(2), 102–109 (2002).
   PubMedGoogle Scholar
• Yee D. The insulin-like growth factor system as a treatment target in breast cancer. Semin. OncoL 29(3 Suppl. 11), 86–95 (2002).
   Google Scholar
• ••Discusses the abundant in vitro, animalmodel and epidemiologic evidence to suggest that IGFs play a role in regulating the malignant phenotype in breast cancer. Insulin-like growth factor action has been implicated in malignant transformation, cellular proliferation, protection from apoptosis and metastasis. Blockade of receptor activation could be a successful method to interrupt IGF-driven processes.
   Google Scholar
• Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. OncoL 20(1), 325–334 (2002).
   Google Scholar
• Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin. OncoL 31(1 Suppl. 3), 21–27 (2004).
   Google Scholar
• Kenney NJ, Saeki T, Gottardis M, Kim N et aL Expression of transforming growth factor a antisense mRNA inhibits the estrogen-induced production of TGF a and estrogen-induced proliferation of estrogen-responsive human breast cancer cells. J Cell Physiol. 156(3), 497–514 (1993).
   Google Scholar
• Bertram J, Killian M, Brysch W, Schlingensiepen KH, Kneba M. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate Antisense oligonucleotides. Biochem. Biophys. Res. Commun. 200(1), 661–667 (1994).
   Google Scholar
• Kashles O, Yarden Y, Fischer R, Ullrich A, Schlessinger J. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. MoL Cell BioL 11(3), 1454–1463 (1991).
   PubMedGoogle Scholar
• Rait AS, Pirollo KF, Xiang L, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. MoL Med. 8(8), 475–486 (2002).
   Google Scholar
• Lazennec G, Alcorn JL, Katzenellenbogen BS. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. MoL Endocrinol. 13(6), 969–980 (1999).
   PubMedGoogle Scholar
• Wright M, Grim J, Deshane J et al. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther. 4(4), 317–322 (1997).
   Google Scholar
• Chang JY, Xia W, Shao R et aL The tumor suppression activity of ElA in HER-2/neu- overexpressing breast cancer. Oncogene 14(5), 561–568 (1997).
   Google Scholar
• Ruppert JM, Wright M, Rosenfeld M et aL Gene therapy strategies for carcinoma of the breast. Breast Cancer Res. Treat. 44(2), 93–114 (1997).
   Google Scholar
• Pandha HS, Martin LA, Rigg A et al. Genetic prodrug activation therapy for breast cancer: a Phase I clinical trial of erbB-2-directed suicide gene expression. Clin. OncoL 17(7), 2180–2189 (1999).
   Google Scholar
• Hernandez-Alcoceba R, Pihalja M, Qian D, Clarke ME New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. Hum. Gene Ther 13(14), 1737–1750 (2002).
   PubMed Web of Science ®Google Scholar
• Todryk SM, Chong H, Vile RG, Pandha H, Lemoine NR. Can immunotherapy by gene transfer tip the balance against colorectal cancer? Gut 43(4), 445–449 (1998).
   Google Scholar
• Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 20(4), 2665–2676 (2000).
   Google Scholar
• Fakhrai H, Shawler DL, Gjerset R et aL Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther 6(5), 591–601 (1995).
   Google Scholar
• Suminami Y, Elder EM, Lotze MT, Whiteside TL. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J. Immunother. Emphasis Tumor ImmunoL 17(4), 238–248 (1995).
   Google Scholar
• Geutskens SB, van der Eb MM, Plomp AC et al. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther 7(16),1410–1416 (2000).
   PubMedGoogle Scholar
• Putzer BM, Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl Acad. ScL USA 94,10889–10894 (1997).
   Google Scholar
• Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. I. Immunol 144(10), 4068–4071 (1990).
   Google Scholar
• Chen Y, Emtage P, Zhu Q et al Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Then 8(4), 316–323 (2001).
   Google Scholar
• Cameron DA, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. Proc. Am. Soc. Clin. Oncol (2004) (Abstract 628).
   Google Scholar